8月3日，科伦博泰生物盘中下跌3.35%，报467.8港元/股，成交额4852.95万港元。
消息面上，公司近期深陷"举报门"舆论风波，一份举报信指控其核心ADC产品芦康沙妥珠单抗涉嫌带金销售、虚开发票套取营销费用等商业贿赂行为，涉及多家顶级三甲医院。公司虽回应称举报内容不属实，但市场情绪仍受冲击。此外，8月1日起被称为"史上最严"的《医药代表管理办法》正式实施，明确划定9条红线，与举报信指控内容高度对应，进一步加剧市场对公司商业化合规性的担忧。生物科技板块整体走弱，信达生物跌3.11%，荣昌生物跌3.67%，三生制药跌2.87%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.